{"news_desk": "Business", "print_page": "1", "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By ANDREW POLLACK and LESLIE PICKER", "person": [{"firstname": "Andrew", "rank": 1, "lastname": "POLLACK", "organization": "", "role": "reported"}, {"firstname": "Leslie", "rank": 2, "lastname": "PICKER", "organization": "", "role": "reported"}]}, "abstract": "Medivation, maker of prostate cancer medication Xtandi, agrees to $14 billion acquisition bid from Pfizer; deal is part of Pfizer's push into oncology drugs, which appear to be resistant to cost-cutting efforts by insurers; Xtandi sales are expected to reach $4 billion annually. ", "type_of_material": "News", "word_count": "1244", "keywords": [{"rank": "1", "value": "Medivation Inc", "is_major": "Y", "name": "organizations"}, {"rank": "2", "value": "Pfizer Inc", "is_major": "Y", "name": "organizations"}, {"rank": "3", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}], "lead_paragraph": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals.", "pub_date": "2016-08-23T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbWide.jpg"}, {"height": 366, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "366", "xlarge": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/08/23/business/dealbook/medivation-pfizer-14-billion-deal.html", "slideshow_credits": null, "blog": [], "_id": "57baea0b95d0e021d7981f10", "headline": {"main": "Pfizer to Buy Cancer Drug Maker in $14 Billion Deal", "print_headline": "Pfizer Pays $14 Billion to Expand in Oncology"}}